{"id":"prophylaxis-with-valganciclovir-plus-everolimus","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Valganciclovir works by inhibiting the viral DNA polymerase, which is essential for viral replication. Everolimus, on the other hand, inhibits the mammalian target of rapamycin (mTOR) pathway, which plays a crucial role in cell growth and proliferation. By combining these two mechanisms, valganciclovir plus everolimus can potentially prevent the activation of latent viruses and reduce the risk of organ rejection in transplant patients.","oneSentence":"Valganciclovir is an antiviral medication that inhibits viral DNA synthesis, while everolimus is an immunosuppressant that inhibits mTOR signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:31.222Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prophylaxis of cytomegalovirus (CMV) infection in transplant patients"},{"name":"Prevention of organ rejection in transplant patients"}]},"trialDetails":[{"nctId":"NCT02188719","phase":"PHASE1","title":"Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-12-17","conditions":"Liver Transplantation","enrollment":15},{"nctId":"NCT00966836","phase":"PHASE3","title":"Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy","status":"UNKNOWN","sponsor":"University of Bologna","startDate":"2009-04","conditions":"Heart Transplantation, Cardiac Allograft Vasculopathy, Cytomegalovirus Infection","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Prophylaxis with valganciclovir plus everolimus","genericName":"Prophylaxis with valganciclovir plus everolimus","companyName":"University of Bologna","companyId":"university-of-bologna","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Valganciclovir is an antiviral medication that inhibits viral DNA synthesis, while everolimus is an immunosuppressant that inhibits mTOR signaling. Used for Prophylaxis of cytomegalovirus (CMV) infection in transplant patients, Prevention of organ rejection in transplant patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}